NetScientific plc (NSCI) ORD GBP0.05
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
NetScientific subsidiary strikes exclusive licensing deal with AstraZeneca
7 June 2021 09:38
(Sharecast News) - Life sciences investment company NetScientific announced on Monday that its subsidiary ProAxsis has entered into an exclusive licensing agreement with AstraZeneca.
Company announcements Announcements
-
ProAxsis secures c.£1.8mn investment
15 April 2024 07:00
NetScientific
-
PDS Strategy Update and 2023 Financial Results
27 March 2024 13:34
NetScientific
-
Business Update
13 March 2024 07:00
NetScientific
-
Exercise of Options and Issue of Shares
5 February 2024 07:00
NetScientific
-
Glycotest secures $1 million investment
23 January 2024 07:00
NetScientific
-
DeepTech Recycling secures £1 million investment
1 December 2023 07:00
NetScientific
-
PDS BioTechnology: Third Quarter Results
14 November 2023 16:39
NetScientific
-
Director/PDMR Shareholding
13 November 2023 07:00
NetScientific
-
PDS Biotech Announces Updated Survival Data
9 November 2023 17:28
NetScientific
-
Ventive secures c.£900,000 investment
6 November 2023 07:00
NetScientific
-
Change of Adviser
2 November 2023 07:00
NetScientific
-
Exercise of Options
13 October 2023 07:00
NetScientific
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.